Neurodegenerative disorders are caused by the death and dysfunction of brain cells, but
despite a huge worldwide effort, no neuroprotective treatments that slow cell death currently …

The standard practice in neuropathology is to diagnose Alzheimer's disease (AD) based on
the distribution and abundance of neurofibrillary tangles and Aβ deposits. However, other …

Background In comparison with late‐onset Alzheimer's disease (LOAD, onset,> 65 years),
early‐age‐of‐onset Alzheimer's disease (EOAD, onset,< 65 years) more often presents with …

Background White matter disease (WMD) is frequently seen in Alzheimer's disease (AD) at
neuropathological examination. It is defined as a subtotal tissue loss with a reduction of …

Posterior cortical atrophy (PCA) is rare neurodegenerative dementia, clinically characterized
by a progressive decline in higher-visual object and space processing. After a brief review of …

A major challenge in the treatment of neurodegenerative disorders is the translation of
effective therapies from the lab to the clinic. One approach to improve this process is the use …

White matter (WM) changes are frequently seen on structural imaging in AD but the clinical
relevance of these changes is uncertain. Frontal WM pathology is often observed upon …

A tissue microarray (TMA) has previously been developed for use in assessment of
neurodegenerative diseases. We investigated the variation of pathology loads in semi …

White matter disease (WMD) with pervasive non-focal subtotal tissue loss is frequently seen
in Alzheimer's disease (AD) upon neuropathological examination. Although WMD has …

The study of neuropathological markers in patients affected by mental/psychiatric disorders
is relevant for the comprehension of the pathogenesis and the correlation with the clinical …